NousCom presents at Agenda Sachs Forum
NousCom will present at the 17th Biotech In Europe Forum for Global Partnering and Investment. The forum wiil take place on 26th-27th September at the Congress Center Basel (switzerland). Feel [...]
NousCom will present at the 17th Biotech In Europe Forum for Global Partnering and Investment. The forum wiil take place on 26th-27th September at the Congress Center Basel (switzerland). Feel [...]
EMBL Heidelberg, Germany Abstract Title: Personalized cancer vaccine based on ChAd vaccine improves over the anti-PD1 activity.
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
